Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
4.120
+0.095 (2.36%)
Feb 21, 2025, 4:00 PM EST - Market closed
Sagimet Biosciences Employees
As of December 31, 2023, Sagimet Biosciences had 10 total employees, including 8 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
10
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,751,700
Market Cap
132.64M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 10 | 0 | - |
Dec 31, 2022 | 10 | 3 | 42.86% |
Dec 31, 2020 | 7 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
SGMT News
- 3 months ago - Sagimet: More Than Just A MASH Drug Development Biotech - Seeking Alpha
- 3 months ago - Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne - PRNewsWire
- 4 months ago - Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat - Seeking Alpha
- 4 months ago - Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology - GlobeNewsWire
- 5 months ago - Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH - GlobeNewsWire
- 5 months ago - Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 months ago - Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit - GlobeNewsWire
- 7 months ago - Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors - GlobeNewsWire